The effectiveness removes the final regulatory hurdle for pricing this secondary offering. With the stock at $37.70 and a $48.7B market cap, the 60M-share block represents ~4.6% of shares outstanding. Expect pricing within 1-2 trading days. The selling stockholder nature (no company proceeds) signals insider monetization, watch for potential downward pressure on the stock as the block is absorbed. The greenshoe option may provide some price support from underwriters.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $37.01entry
- T+1 · 6mo ago −2.30%α −2.88% · $36.16
- T+5 · 6mo ago −3.40%α −5.06% · $35.75
- T+20 · 5mo ago −4.59%α −3.18% · $35.31
- T+60 · 3mo ago −7.81%α −11.00% · $34.12
Price Chart
How similar events traded
Executive Summary
The SEC declared effective Medline Inc.'s registration statement (File No. 333-296044) on May 21, 2026, covering a secondary offering of 60,000,000 shares of Class A common stock by selling stockholders. The company will not receive any proceeds from this offering, which follows its December 2025 IPO and a prior secondary filing. The effectiveness clears the path for pricing and closing of the follow-on offering, with the underwriters having a 30-day option to purchase an additional 9,000,000 shares.
Key Facts
- EFFECT notice for File No. 333-296044, declared effective May 21, 2026
- Covers secondary offering of 60,000,000 shares of Class A common stock by selling stockholders
- Company receives no proceeds from the offering
- Underwriters have 30-day option to purchase up to an additional 9,000,000 shares
- S-1 filed May 20, 2026, priced at $37.70 per share (May 19 close)
- Follows December 2025 IPO (179M shares) and a prior 75M-share secondary filing from March 2026
Financial Impact
Secondary offering of 60M shares at $37.70/share implies ~$2.26B in gross proceeds to selling stockholders; potential additional 9M shares via greenshoe could add ~$339M. No proceeds to the company.
Risk Factors
- Secondary offering by selling stockholders may create overhang and downward price pressure
- Pricing below the May 19 close of $37.70 could signal weak demand
- Insider selling pattern (third secondary offering in 6 months) may concern investors
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001735 |
| Document: 9999999995-26-001735-index.html | 9999999995-26-001735 |
| Document: 9999999995-26-001735.txt | 9999999995-26-001735 |
Track record
30 reports on MDLN
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $36.40 Now $39.17 −7.61% settles Nov 23
- Nov 16, 2026today S-1 Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $39.17 −3.78% ▼ −3.78% −2.09% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $40.35 to $42.16 Now $39.17 −2.92% ▲ +4.49% +5.40% vs SPY
- Nov 2, 202613d ago Institutional Cluster Bearish 4/10 Entry $34.09 to $40.91 Now $39.17 −14.90% ▼ −20.01% −20.59% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $32.12 to $39.64 Now $39.17 +21.95% ▲ +23.41% +26.12% vs SPY
- Oct 21, 202626d ago 8-K Bearish 6/10 Entry $34.88 to $32.00 Now $39.17 −12.30% ▲ +8.26% +8.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers